Analysts expect over 2019 decreasing revenue Novartis, huge dividend

Tomorrow the Swiss Novartis will publish its past quarters figures. For this year Novartis's revenue will be around 47,16 billion CHF. This is according to the average of the analysts' estimates. This is rather significant lower than 2018's revenue of 53,17 billion CHF.

Historical revenues and results Novartis plus estimates 2019

fundamental research

The analysts expect for 2019 a net profit of 11,77 billion CHF. Most of the analysts anticipate on a profit per share of 5,16 CHF. With this the price/earnings-ratio is 16,5.

Huge dividend Novartis

Per share the analysts expect a dividend of 2,97 CHF per share. Thus the dividend yield equals 3,49 percent. The average dividend yield of the pharmaceutical companies equals an attractive4 percent.

Latest estimates around 92 CHF

The most recent recommendations for the pharmaceutical company are from Deutsche Bank, JP Morgan and Goldman Sachs.

Novartis's market capitalization is based on the number of outstanding shares around 197,31 billion CHF. The Novartis stock was the past 12 months quite volatile. Since last October the stock is 15 percent higher. This year the stock price moved between 72 and 94 CHF.

Historical stock prices Novartis period 2007-2019

fundamental research novartis

Click here for dividend . At 11.30 the stock trades 0,43 percent lower at 85,14 CHF.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.